Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Case Rep Oncol
Autores principales: Carter, Corey A., Oronsky, Bryan, Caroen, Scott, Scicinski, Jan, Degesys, Aiste, Cabrales, Pedro, Reid, Tony R., Brzezniak, Christina
Formato: Artigo
Lenguaje:Inglês
Publicado: S. Karger AG 2016
Materias:
Published online: May, 2016
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924447/
https://ncbi.nlm.nih.gov/pubmed/27403127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000446209
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares